Overview Study of LM-302 in Patients With Advance Solid Tumors Status: Not yet recruiting Trial end date: 2025-06-08 Target enrollment: Participant gender: Summary A Phase I/II Study of LM-302 in Patients with CLDN18.2-Positive Advanced Solid Tumors Phase: Phase 1/Phase 2 Details Lead Sponsor: LaNova Medicines Zhejiang Co., Ltd.